Signature Wealth Management Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Signature Wealth Management Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-66,666	Closed	-$528K	–	104
2024 Q4	$528K	Hold	66,666	–	–	0.36%	56
2024 Q3	$555K	Hold	66,666	–	–	0.4%	53
2024 Q2	$423K	Hold	66,666	–	–	0.32%	59
2024 Q1	$404K	Hold	66,666	–	–	0.33%	61
2023 Q4	$405K	Hold	66,666	–	–	0.35%	62
2023 Q3	$281K	Sell	66,666 -21,000	-24%	-$78.3K	0.28%	72
2023 Q2	$272K	Hold	87,666	–	–	0.25%	75
2023 Q1	$122K	Hold	87,666	–	–	0.11%	100
2022 Q4	$174K	Hold	87,666	–	–	0.17%	91
2022 Q3	$177K	Hold	87,666	–	–	0.19%	89
2022 Q2	$279K	Hold	87,666	–	–	0.29%	79
2022 Q1	$366K	Hold	87,666	–	–	0.31%	72
2021 Q4	$420K	Hold	87,666	–	–	0.36%	63
2021 Q3	$468K	Hold	87,666	–	–	0.42%	61
2021 Q2	$449K	Hold	87,666	–	–	0.41%	61
2021 Q1	$590K	Hold	87,666	–	–	0.57%	48
2020 Q4	$401K	Buy	+87,666	New	+$388K	0.4%	58

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Signature Wealth Management Partners's AMRX Position: Q1 2025 in Review

Signature Wealth Management Partners sold out of Amneal Pharmaceuticals (AMRX) in Q1 2025, closing a stake of 66,666 shares — an estimated $528K sold.

Signature Wealth Management Partners first reported a position in AMRX in Q4 2020 and held it in 17 quarters. The position peaked at $590K in Q1 2021. 237 funds tracked by Wall St. Rank hold AMRX as of Q1 2025.

Signature Wealth Management Partners reported no remaining Amneal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Signature Wealth Management Partners sold 66,666 Amneal Pharmaceuticals shares in Q1 2025, an estimated $528K.
Signature Wealth Management Partners first reported a position in Amneal Pharmaceuticals in Q4 2020 and held it in 17 quarters.
Signature Wealth Management Partners's Amneal Pharmaceuticals position peaked at $590K in Q1 2021.
237 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2025.

Based on Signature Wealth Management Partners's 13F filing for Q1 2025, filed 8 May 2025.